Hanley Patrick J, Bollard Catherine M, Brunstein Claudio G
Program for Cell Enhancement and Technologies for Immunotherapy, Children's National Medical Center and The George Washington University, Washington, DC, USA; Center for Cancer and Immunology Research, Children's National Medical Center and The George Washington University, Washington, DC, USA; Division of Blood and Marrow Transplantation, Children's National Medical Center and The George Washington University, Washington, DC, USA; Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Medical Center and The George Washington University, Washington, DC, USA.
Program for Cell Enhancement and Technologies for Immunotherapy, Children's National Medical Center and The George Washington University, Washington, DC, USA; Center for Cancer and Immunology Research, Children's National Medical Center and The George Washington University, Washington, DC, USA; Division of Blood and Marrow Transplantation, Children's National Medical Center and The George Washington University, Washington, DC, USA; Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Medical Center and The George Washington University, Washington, DC, USA.
Cytotherapy. 2015 Jun;17(6):749-755. doi: 10.1016/j.jcyt.2014.12.007. Epub 2015 Jan 24.
Cord blood transplantation, an alternative to traditional stem cell transplants (bone marrow or peripheral blood stem cell transplantation), is an attractive option for patients lacking suitable stem cell transplant donors. Cord blood units have also proven to be a valuable donor source for the development of cellular therapeutics. Virus-specific T cells and regulatory T cells are two cord blood-derived products that have shown promise in early-phase clinical trials to prevent and/or treat viral infections and graft-versus-host disease, respectively. We describe how current strategies that use cord blood-derived regulatory T cells and virus-specific T cells have been developed to improve outcomes for cord blood transplant recipients.
脐带血移植是传统干细胞移植（骨髓或外周血干细胞移植）的替代方法，对于缺乏合适干细胞移植供体的患者来说是一个有吸引力的选择。脐带血单位也已被证明是细胞治疗开发的宝贵供体来源。病毒特异性T细胞和调节性T细胞是两种源自脐带血的产品，分别在预防和/或治疗病毒感染及移植物抗宿主病的早期临床试验中显示出前景。我们描述了目前如何开发使用源自脐带血的调节性T细胞和病毒特异性T细胞的策略，以改善脐带血移植受者的治疗效果。
